First human MAb offers RA patients effective option

January 20, 2003

Patients with rheumatoid arthritis (RA) now have a first-of-its-kind therapeutic option that is safe, convenient, and effective. The FDA recently approved adalimumab (Humira, Abbott Laboratories) for reducing the signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active RA who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). The approval of adalimumab comes just nine months after regulatory submission. Adalimumab will be available in pharmacies by mid-January.